HUE049012T2 - Antitestek S. aureus felszíni determinánsok ellen - Google Patents

Antitestek S. aureus felszíni determinánsok ellen

Info

Publication number
HUE049012T2
HUE049012T2 HUE13852597A HUE13852597A HUE049012T2 HU E049012 T2 HUE049012 T2 HU E049012T2 HU E13852597 A HUE13852597 A HU E13852597A HU E13852597 A HUE13852597 A HU E13852597A HU E049012 T2 HUE049012 T2 HU E049012T2
Authority
HU
Hungary
Prior art keywords
antibodies against
surface determinants
aureus surface
aureus
determinants
Prior art date
Application number
HUE13852597A
Other languages
English (en)
Hungarian (hu)
Inventor
Bret Sellman
Christine Tkaczyk
Partha Chowdhury
Lei Hua
Peter Pavlik
Rebecca Buonpane
Chew-Shun Chang
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of HUE049012T2 publication Critical patent/HUE049012T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HUE13852597A 2012-11-06 2013-11-06 Antitestek S. aureus felszíni determinánsok ellen HUE049012T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261723137P 2012-11-06 2012-11-06
US201361782405P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
HUE049012T2 true HUE049012T2 (hu) 2020-09-28

Family

ID=50685304

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13852597A HUE049012T2 (hu) 2012-11-06 2013-11-06 Antitestek S. aureus felszíni determinánsok ellen

Country Status (16)

Country Link
US (3) US9879070B2 (show.php)
EP (2) EP3640338A1 (show.php)
JP (2) JP6694269B2 (show.php)
KR (1) KR102288394B1 (show.php)
CN (2) CN109553681A (show.php)
AU (2) AU2013341361A1 (show.php)
BR (1) BR112015010125A2 (show.php)
CA (1) CA2890427C (show.php)
DK (1) DK2917360T3 (show.php)
ES (1) ES2776179T3 (show.php)
HU (1) HUE049012T2 (show.php)
MX (2) MX375324B (show.php)
PL (1) PL2917360T3 (show.php)
RU (1) RU2698131C2 (show.php)
SG (2) SG11201503232TA (show.php)
WO (1) WO2014074540A2 (show.php)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2826566C (en) * 2011-02-08 2022-09-13 Medimmune, Llc Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
JP6058645B2 (ja) 2011-06-10 2017-01-11 メディミューン，エルエルシー 抗シュードモナス属（Ｐｓｅｕｄｏｍｏｎａｓ）Ｐｓｌ結合分子およびその使用
CA3161431A1 (en) 2011-11-07 2013-05-16 Medimmune Limited Combination therapies using anti-pseudomonas psl and pcrv binding molecules
US9988439B2 (en) 2011-12-23 2018-06-05 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
WO2013096948A1 (en) 2011-12-23 2013-06-27 Lydon Nicholas B Immunoglobulins and variants directed against pathogenic microbes
CN109553681A (zh) * 2012-11-06 2019-04-02 米迪缪尼有限公司 金黄色葡萄球菌表面决定簇的抗体
AU2013341421A1 (en) 2012-11-06 2015-06-04 Medimmune, Llc Methods of treating S. aureus-associated diseases
KR20210047355A (ko) * 2014-06-03 2021-04-29 엑스바이오테크 인코포레이티드 스타필로코커스 아우레우스 감염의 치료 및 예방을 위한 조성물 및 방법
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
US20180017559A1 (en) * 2014-08-12 2018-01-18 Arsanis Biosciences Gmbh Predicting s. aureus disease
WO2016073860A1 (en) * 2014-11-06 2016-05-12 Medimmune, Llc Binding molecules specific for staphylococcus protein a and uses thereof
FR3033333A1 (fr) * 2015-03-06 2016-09-09 Commissariat Energie Atomique Procede et dispositif pour detecter en temps reel un compose secrete et la cible secretrice ainsi que leurs utilisations
MX2017012775A (es) * 2015-04-17 2019-04-29 Arsanis Biosciences Gmbh Preparacion combinatoria de anticuerpos anti-staphylococcus aureus.
WO2017075188A2 (en) * 2015-10-30 2017-05-04 Medimmune, Llc Methods of using anti-alpha toxin antibody
CN105424930A (zh) * 2015-11-23 2016-03-23 天津科技大学 一种快速检测金黄色葡萄球菌的方法
MY199789A (en) * 2017-09-29 2023-11-23 Regeneron Pharma Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof
US11155606B2 (en) 2018-07-24 2021-10-26 Medimmune, Llc Antibody directed against S. aureus clumping factor a (ClfA)
CA3115633A1 (en) 2018-10-09 2020-04-16 Medimmune, Llc Combinations of anti-staphylococcus aureus antibodies
MX2021004114A (es) 2018-10-09 2021-07-16 Medimmune Llc Anticuerpos dirigidos contra leucotoxinas de staphylococcus aureus.
US12459991B2 (en) 2019-02-12 2025-11-04 Regeneron Pharmaceuticals, Inc. Compositions and methods for using bispecific antibodies to bind complement and a target antigen
EP3938388A1 (en) 2019-03-13 2022-01-19 MedImmune, LLC Decreasings staphylococcus aureus infections in colonized patients
WO2020210650A1 (en) 2019-04-12 2020-10-15 Medimmune, Llc Neutralization of tgf-beta or alpha-v-beta-8 integrin for s. aureus infections
CN112538112B (zh) * 2019-09-20 2023-10-27 迈威(上海)生物科技股份有限公司 抗α-溶血素的抗体及其应用
KR102397684B1 (ko) * 2019-12-09 2022-05-13 (주)옵토레인 항체의 항원 결합 부위에 결합하는 펩티드 및 이를 이용한 분석 방법
KR102504175B1 (ko) * 2020-06-17 2023-02-28 (주)옵토레인 항체의 항원 결합 부위에 결합하는 펩타이드, 이를 이용한 약물 복합체, 바이오센서 및 분석 방법
KR102674098B1 (ko) * 2021-01-14 2024-06-12 (주)옵토레인 스위칭 펩티드 및 이를 이용한 멀티플렉스 면역분석 방법
KR102674109B1 (ko) * 2021-01-14 2024-06-12 (주)옵토레인 스위칭 펩티드, 이를 포함하는 면역분석 장치 및 이를 이용한 면역분석 방법
KR102674120B1 (ko) * 2021-01-18 2024-06-12 (주)옵토레인 스위칭 펩티드 및 이를 이용한 면역분석 방법

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2017198A (en) * 1931-10-17 1935-10-15 Anglada Motor Corp Cuff valve engine
US20030044772A1 (en) * 1997-08-04 2003-03-06 Applied Molecular Evolution [Formerly Ixsys] Methods for identifying ligand specific binding molecules
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7396917B2 (en) * 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US7214786B2 (en) * 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
ATE524195T1 (de) * 2001-01-26 2011-09-15 Inhibitex Inc Monoklonale antikörper gegen das clfa-protein und verfahren zur verwendung bei der behandlung bzw. pr vention von infektionen
EP1638514A4 (en) 2003-06-06 2009-11-18 Medimmune Inc USE OF EPHA4 AND MODULATOR OR EPHA4 FOR THE DIAGNOSIS, TREATMENT AND PREVENTION OF CANCER
WO2005019267A2 (en) * 2003-08-12 2005-03-03 Dyax Corp. Tie1-binding ligands
JP2008515774A (ja) * 2004-08-03 2008-05-15 ダイアックス コーポレイション ｈＫ１結合タンパク質
US20080050361A1 (en) 2004-10-25 2008-02-28 Heinrichs David E Staphylococcus aureas specific anti-infectives
CA2638833A1 (en) * 2006-03-06 2007-09-13 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
US7910703B2 (en) * 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
EP2719397A1 (en) * 2006-06-12 2014-04-16 GlaxoSmithKline Biologicals SA Use of alpha-toxin for treating and preventing staphylococcus infections
CA2667788A1 (en) * 2006-10-30 2008-12-18 The University Of Western Ontario Staphylococcus aureus specific anti-infectives
US9526774B1 (en) * 2006-11-06 2016-12-27 Microvax, Llc Methods and compositions for suppressing virulence of methicillin resistant Staphylococcus aureus
HRP20161305T1 (hr) * 2008-01-31 2017-01-27 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Liječenje mikrobnih infekcija
WO2009140236A2 (en) * 2008-05-12 2009-11-19 Strox Biopharmaceuticals, Llc Staphylococcus aureus-specific antibody preparations
WO2010005513A2 (en) * 2008-06-30 2010-01-14 The Texas A&M University System Crystal structure of staphylococcus aureus clumping factor a in complex with fibrinogen derived peptide and uses thereof
EP2341929B1 (en) * 2008-10-06 2017-01-25 University Of Chicago Compositions and methods related to bacterial emp proteins
EP2432499A2 (en) * 2009-05-20 2012-03-28 Schering Corporation Modulation of pilr receptors to treat microbial infections
CN102481352A (zh) * 2009-06-22 2012-05-30 惠氏有限责任公司 金黄色葡萄球菌抗原的免疫原性组合物
DK2454284T3 (en) * 2009-07-15 2018-07-02 Aimm Therapeutics Bv GRAM POSITIVE BACTERIA-SPECIFIC BINDING COMPOUNDS
GB0913680D0 (en) * 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
EP2284193A1 (en) * 2009-08-10 2011-02-16 Kenta Biotech AG Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation
EP2516467A2 (en) * 2009-12-23 2012-10-31 Emergent Product Development Seattle, LLC Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
JP2013523818A (ja) * 2010-04-05 2013-06-17 ザ・ユニバーシティー・オブ・シカゴ 免疫反応のエンハンサーとしてのプロテインＡ（ＳｐＡ）抗体に関連する組成物および方法
US9095540B2 (en) * 2010-09-09 2015-08-04 The University Of Chicago Methods and compositions involving protective staphylococcal antigens
US20120202047A1 (en) 2011-02-07 2012-08-09 Baker Hughes Incorporated Nano-coatings for articles
CA2826566C (en) * 2011-02-08 2022-09-13 Medimmune, Llc Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
US9556281B2 (en) * 2011-08-15 2017-01-31 The University Of Chicago Compositions and methods related to antibodies to staphylococcal protein A
RS60499B1 (sr) * 2011-12-20 2020-08-31 Medimmune Llc Modifikovani polipeptidi za bispecifične skelete antitela
PL2844275T3 (pl) * 2012-04-26 2021-03-08 University Of Chicago Koagulazy gronkowcowe stanowiące antygeny i sposoby ich zastosowania
AU2013341421A1 (en) * 2012-11-06 2015-06-04 Medimmune, Llc Methods of treating S. aureus-associated diseases
CN109553681A (zh) * 2012-11-06 2019-04-02 米迪缪尼有限公司 金黄色葡萄球菌表面决定簇的抗体
CA2898472C (en) * 2013-02-15 2023-03-07 Immunomedics, Inc. Chimeric and humanized anti-histone antibodies
CA2952930A1 (en) * 2013-10-15 2015-04-23 The Texas A&M University System Compositions and the use of a fibrinogn binding motif presence in efb and coa for vaccine against staphylococcus aureus and drug delivery
US20170023569A1 (en) * 2014-01-10 2017-01-26 University Of Rochester Diagnostic device and method for detection of staphylococcus infection
WO2015112895A2 (en) * 2014-01-24 2015-07-30 Church William R Antibody specific to staphylococcus aureus, therapeutic method and detection method using same
KR20210047355A (ko) * 2014-06-03 2021-04-29 엑스바이오테크 인코포레이티드 스타필로코커스 아우레우스 감염의 치료 및 예방을 위한 조성물 및 방법
TWI719938B (zh) * 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
WO2016073860A1 (en) * 2014-11-06 2016-05-12 Medimmune, Llc Binding molecules specific for staphylococcus protein a and uses thereof
MX2017012775A (es) 2015-04-17 2019-04-29 Arsanis Biosciences Gmbh Preparacion combinatoria de anticuerpos anti-staphylococcus aureus.
WO2017075188A2 (en) * 2015-10-30 2017-05-04 Medimmune, Llc Methods of using anti-alpha toxin antibody
WO2017186928A1 (en) * 2016-04-29 2017-11-02 Curevac Ag Rna encoding an antibody
CA3030154A1 (en) * 2016-07-08 2018-01-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric dengue/zika viruses live-attenuated zika virus vaccines
US11155606B2 (en) * 2018-07-24 2021-10-26 Medimmune, Llc Antibody directed against S. aureus clumping factor a (ClfA)
CA3115633A1 (en) * 2018-10-09 2020-04-16 Medimmune, Llc Combinations of anti-staphylococcus aureus antibodies
MX2021004114A (es) * 2018-10-09 2021-07-16 Medimmune Llc Anticuerpos dirigidos contra leucotoxinas de staphylococcus aureus.
EP3938388A1 (en) * 2019-03-13 2022-01-19 MedImmune, LLC Decreasings staphylococcus aureus infections in colonized patients

Also Published As

Publication number Publication date
RU2019122610A (ru) 2020-02-18
ES2776179T3 (es) 2020-07-29
CN109553681A (zh) 2019-04-02
MX2022008079A (es) 2022-07-11
KR20150094621A (ko) 2015-08-19
WO2014074540A3 (en) 2014-07-10
AU2018241107B2 (en) 2020-09-17
JP6694269B2 (ja) 2020-05-13
WO2014074540A2 (en) 2014-05-15
DK2917360T3 (da) 2020-03-30
EP2917360B1 (en) 2020-01-08
RU2698131C2 (ru) 2019-08-22
HK1215054A1 (en) 2016-08-12
EP3640338A1 (en) 2020-04-22
MX2015005477A (es) 2015-11-30
HK1215452A1 (zh) 2016-08-26
US20150291685A1 (en) 2015-10-15
US11447543B2 (en) 2022-09-20
BR112015010125A2 (pt) 2017-08-22
CN104968797B (zh) 2018-11-30
RU2015121624A (ru) 2016-12-27
US9879070B2 (en) 2018-01-30
SG11201503232TA (en) 2015-05-28
CA2890427C (en) 2022-05-31
CN104968797A (zh) 2015-10-07
AU2013341361A1 (en) 2015-06-04
JP2016507470A (ja) 2016-03-10
PL2917360T3 (pl) 2020-06-29
CA2890427A1 (en) 2014-05-15
JP2019089801A (ja) 2019-06-13
US20200407429A1 (en) 2020-12-31
EP2917360A2 (en) 2015-09-16
SG10201703678TA (en) 2017-06-29
US10730934B2 (en) 2020-08-04
EP2917360A4 (en) 2017-01-25
AU2018241107A1 (en) 2018-10-25
MX375324B (es) 2025-03-06
KR102288394B1 (ko) 2021-08-09
US20190016787A1 (en) 2019-01-17

Similar Documents

Publication Publication Date Title
CY2024011I1 (el) Αντισωματα anti-fcrn
HUE049012T2 (hu) Antitestek S. aureus felszíni determinánsok ellen
FR3006466B3 (fr) .
DK2934584T3 (da) Anti-gdf15-antistoffer
HRP20181646T1 (hr) Konjugati pirolobenzodiazepin - anti-psma protutijela
BR112015004233A2 (pt) inalador.
BR112015004230A2 (pt) inalador.
BR112015002960A2 (pt) aparelho de gravação.
FR3007989B1 (fr) Autoinjecteur.
FR3013601B1 (fr) Autoinjecteur.
DK2855530T3 (da) Anti-transglutaminase 2-antistoffer
DK2828292T3 (da) Jcv-neutraliserende antistoffer
DK2935330T3 (da) Anti-notch3-antistoffer
FR2986872B1 (fr) .
FR2996109B1 (fr) Applicateur chauffant.
FR3001302B1 (fr) .
FR2978994B1 (fr) .
DK2500470T3 (da) Hoved-arbejdsvogn
BR112014027645A2 (pt) 5-halogenopirazol bifenilcarboxamidas.
FR3001303B1 (fr) .
BR112014021674A2 (pt) arilpirrolidinas pesticidas
ES2396651B2 (es) Material biosanitario antiulcera.
FR2990870B1 (fr) Autoinjecteur.
FR2996866B1 (fr) Entrevous
FR2980994B1 (fr) Prehenseur multi-plaquettes.